{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T00:06:51Z","timestamp":1794442011471,"version":"4.9.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Liaoning Province","award":["2023-MS-061"],"award-info":[{"award-number":["2023-MS-061"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"DOI":"10.1007\/s00018-026-06121-4","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:04:27Z","timestamp":1772557467000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["LILRB4 shapes an immunosuppressive microenvironment to drive cervical cancer progression through tumor-infiltrating myeloid cell expansion and CD8+ T-cell suppression"],"prefix":"10.1007","volume":"83","author":[{"given":"Yue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2592-9138","authenticated-orcid":false,"given":"Rui","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"6121_CR1","doi-asserted-by":"publisher","first-page":"105671","DOI":"10.1016\/j.jcv.2024.105671","volume":"172","author":"M Poljak","year":"2024","unstructured":"Poljak M, O\u0161trbenk Valen\u010dak A, Cuschieri K, Bohinc KB, Arbyn M (2024) 2023 global inventory of commercial molecular tests for human papillomaviruses (HPV). J Clin Virol 172:105671. https:\/\/doi.org\/10.1016\/j.jcv.2024.105671","journal-title":"J Clin Virol"},{"key":"6121_CR2","doi-asserted-by":"publisher","unstructured":"\u0218andru F, Radu A-M, Petca A, Dumitra\u0219cu MC, Petca R-C, Roman A-M (2024) Unveiling the therapeutic horizon: HPV vaccines and their impact on cutaneous Diseases-A comprehensive review. Vaccines (Basel) 12. https:\/\/doi.org\/10.3390\/vaccines12030228","DOI":"10.3390\/vaccines12030228"},{"key":"6121_CR3","doi-asserted-by":"publisher","first-page":"106777","DOI":"10.1016\/j.phrs.2023.106777","volume":"191","author":"X Zhang","year":"2023","unstructured":"Zhang X, Yu S, Li X, Wen X, Liu S, Zu R et al (2023) Research progress on the interaction between oxidative stress and platelets: another avenue for cancer? Pharmacol Res 191:106777. https:\/\/doi.org\/10.1016\/j.phrs.2023.106777","journal-title":"Pharmacol Res"},{"key":"6121_CR4","doi-asserted-by":"publisher","first-page":"1251913","DOI":"10.3389\/fcimb.2023.1251913","volume":"13","author":"JG Gon\u00e7alves-Nobre","year":"2023","unstructured":"Gon\u00e7alves-Nobre JG, Matos A, Carreira M, Santos AC, Veiga LC, Ginete C et al (2023) The interplay between HPV, other sexually transmissible infections and genital Microbiome on cervical microenvironment (MicroCervixHPV study). Front Cell Infect Microbiol 13:1251913. https:\/\/doi.org\/10.3389\/fcimb.2023.1251913","journal-title":"Front Cell Infect Microbiol"},{"key":"6121_CR5","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1016\/j.celrep.2016.04.084","volume":"15","author":"A-M Georgoudaki","year":"2016","unstructured":"Georgoudaki A-M, Prokopec KE, Boura VF, Hellqvist E, Sohn S, \u00d6stling J et al (2016) Reprogramming Tumor-Associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep 15:2000\u20132011. https:\/\/doi.org\/10.1016\/j.celrep.2016.04.084","journal-title":"Cell Rep"},{"key":"6121_CR6","doi-asserted-by":"publisher","unstructured":"Wakabayashi R, Nakahama Y, Nguyen V, Espinoza JL (2019) The Host-Microbe interplay in human Papillomavirus-Induced carcinogenesis. Microorganisms 7 https:\/\/doi.org\/10.3390\/microorganisms7070199","DOI":"10.3390\/microorganisms7070199"},{"key":"6121_CR7","doi-asserted-by":"publisher","unstructured":"Jain M, Yadav D, Jarouliya U, Chavda V, Yadav AK, Chaurasia B et al (2023) Epidemiology, molecular Pathogenesis, Immuno-Pathogenesis, immune escape mechanisms and vaccine evaluation for HPV-Associated carcinogenesis. Pathogens 12. https:\/\/doi.org\/10.3390\/pathogens12121380","DOI":"10.3390\/pathogens12121380"},{"key":"6121_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ygyno.2019.12.034","volume":"157","author":"AD Santin","year":"2020","unstructured":"Santin AD, Deng W, Frumovitz M, Buza N, Bellone S, Huh W et al (2020) Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528\/NRG-GY002). Gynecol Oncol 157:161\u2013166. https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.034","journal-title":"Gynecol Oncol"},{"key":"6121_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1006\/smim.2000.0214","volume":"12","author":"M Colonna","year":"2000","unstructured":"Colonna M, Nakajima H, Cella M (2000) A family of inhibitory and activating Ig-like receptors that modulate function of lymphoid and myeloid cells. Semin Immunol 12:121\u2013127","journal-title":"Semin Immunol"},{"key":"6121_CR10","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1084\/jem.185.10.1743","volume":"185","author":"M Cella","year":"1997","unstructured":"Cella M, D\u00f6hring C, Samaridis J, Dessing M, Brockhaus M, Lanzavecchia A et al (1997) A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med 185:1743\u20131751","journal-title":"J Exp Med"},{"key":"6121_CR11","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/87749","volume":"2","author":"MC Castells","year":"2001","unstructured":"Castells MC, Klickstein LB, Hassani K, Cumplido JA, Lacouture ME, Austen KF et al (2001) gp49B1-alpha(v)beta3 interaction inhibits antigen-induced mast cell activation. Nat Immunol 2:436\u2013442","journal-title":"Nat Immunol"},{"key":"6121_CR12","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1002\/eji.200737550","volume":"38","author":"S Kasai","year":"2008","unstructured":"Kasai S, Inui M, Nakamura K, Kakizaki Y, Endo S, Nakamura A et al (2008) A novel regulatory role of gp49B on dendritic cells in T-cell priming. Eur J Immunol 38:2426\u20132437. https:\/\/doi.org\/10.1002\/eji.200737550","journal-title":"Eur J Immunol"},{"key":"6121_CR13","doi-asserted-by":"publisher","first-page":"635","DOI":"10.4049\/jimmunol.1302772","volume":"193","author":"S Fukao","year":"2014","unstructured":"Fukao S, Haniuda K, Nojima T, Takai T, Kitamura D (2014) gp49B-mediated negative regulation of antibody production by memory and marginal zone B cells. J Immunol 193:635\u2013644. https:\/\/doi.org\/10.4049\/jimmunol.1302772","journal-title":"J Immunol"},{"key":"6121_CR14","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.4049\/jimmunol.170.8.4095","volume":"170","author":"X Gu","year":"2003","unstructured":"Gu X, Laouar A, Wan J, Daheshia M, Lieberman J, Yokoyama WM et al (2003) The gp49B1 inhibitory receptor regulates the IFN-gamma responses of T cells and NK cells. J Immunol 170:4095\u20134101","journal-title":"J Immunol"},{"key":"6121_CR15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41423-019-0321-2","volume":"17","author":"Z Li","year":"2020","unstructured":"Li Z, Deng M, Huang F, Jin C, Sun S, Chen H et al (2020) LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells. Cell Mol Immunol 17:272\u2013282. https:\/\/doi.org\/10.1038\/s41423-019-0321-2","journal-title":"Cell Mol Immunol"},{"key":"6121_CR16","doi-asserted-by":"publisher","unstructured":"Sharma N, Atolagbe OT, Ge Z, Allison JP (2021) LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. J Exp Med 218. https:\/\/doi.org\/10.1084\/jem.20201811","DOI":"10.1084\/jem.20201811"},{"key":"6121_CR17","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/1541-7786.MCR-20-0622","volume":"19","author":"L Singh","year":"2021","unstructured":"Singh L, Muise ES, Bhattacharya A, Grein J, Javaid S, Stivers P et al (2021) ILT3 (LILRB4) promotes the immunosuppressive function of Tumor-Educated human monocytic Myeloid-Derived suppressor cells. Mol Cancer Res 19:702\u2013716. https:\/\/doi.org\/10.1158\/1541-7786.MCR-20-0622","journal-title":"Mol Cancer Res"},{"key":"6121_CR18","doi-asserted-by":"publisher","first-page":"1645019","DOI":"10.3389\/fimmu.2025.1645019","volume":"16","author":"Y Li","year":"2025","unstructured":"Li Y, Deng J, Liu Y, Yu S (2025) HPV infection and the immune microenvironment in cervical cancer. Front Immunol 16:1645019. https:\/\/doi.org\/10.3389\/fimmu.2025.1645019","journal-title":"Front Immunol"},{"key":"6121_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.canlet.2020.10.034","volume":"497","author":"Y Yuan","year":"2020","unstructured":"Yuan Y, Cai X, Shen F, Ma F (2020) HPV post-infection microenvironment and cervical cancer. Cancer Lett 497:243\u2013254. https:\/\/doi.org\/10.1016\/j.canlet.2020.10.034","journal-title":"Cancer Lett"},{"key":"6121_CR20","doi-asserted-by":"publisher","unstructured":"Liu X, Quan N (2015) Immune cell isolation from mouse femur bone marrow. Bio Protoc 20:e1631. https:\/\/doi.org\/10.21769\/bioprotoc.1631","DOI":"10.21769\/bioprotoc.1631"},{"key":"6121_CR21","doi-asserted-by":"publisher","unstructured":"Olmedo-Nieva L, Mu\u00f1oz-Bello JO, Mart\u00ednez-Ram\u00edrez I, Mart\u00ednez-Guti\u00e9rrez AD, Ortiz-Pedraza Y, Gonz\u00e1lez-Espinosa C et al (2022) RIPOR2 expression decreased by HPV-16 E6 and E7 oncoproteins: an opportunity in the search for prognostic biomarkers in cervical cancer. Cells 11. https:\/\/doi.org\/10.3390\/cells11233942","DOI":"10.3390\/cells11233942"},{"key":"6121_CR22","doi-asserted-by":"publisher","first-page":"e21401","DOI":"10.1096\/fj.202000528RR","volume":"35","author":"Z Chen","year":"2021","unstructured":"Chen Z, Dong D, Zhu Y, Pang N, Ding J (2021) The role of Tim-3\/Galectin-9 pathway in T-cell function and prognosis of patients with human papilloma virus-associated cervical carcinoma. FASEB J 35:e21401. https:\/\/doi.org\/10.1096\/fj.202000528RR","journal-title":"FASEB J"},{"key":"6121_CR23","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1200\/JCO.23.02479","volume":"42","author":"P-H Luo","year":"2024","unstructured":"Luo P-H, Mo D-C, Wang H-L, Liang X-J, Huang J-F (2024) Predicted value of PD-L1 for patients with cervical cancer treated with pembrolizumab. J Clin Oncol 42:1596. https:\/\/doi.org\/10.1200\/JCO.23.02479","journal-title":"J Clin Oncol"},{"key":"6121_CR24","doi-asserted-by":"publisher","unstructured":"Ni H, Zhang H, Li L, Huang H, Guo H, Zhang L et al (2022) T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer. J Immunother Cancer 10. https:\/\/doi.org\/10.1136\/jitc-2022-005151","DOI":"10.1136\/jitc-2022-005151"},{"key":"6121_CR25","doi-asserted-by":"publisher","first-page":"720447","DOI":"10.3389\/fonc.2021.720447","volume":"11","author":"S Zhang","year":"2021","unstructured":"Zhang S, Wan J, Chen M, Cai D, Xu J, Chen Q (2021) Tumor-Infiltrating CD8\u2009+\u2009T cells driven by the immune Checkpoint-Associated gene IDO1 are associated with cervical cancer prognosis. Front Oncol 11:720447. https:\/\/doi.org\/10.3389\/fonc.2021.720447","journal-title":"Front Oncol"},{"key":"6121_CR26","doi-asserted-by":"publisher","first-page":"101374","DOI":"10.1016\/j.xcrm.2023.101374","volume":"5","author":"Y Wang","year":"2024","unstructured":"Wang Y, Sun Y, Deng S, Liu J, Yu J, Chi H et al (2024) Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors. Cell Rep Med 5:101374. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101374","journal-title":"Cell Rep Med"},{"key":"6121_CR27","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","volume":"562","author":"M Deng","year":"2018","unstructured":"Deng M, Gui X, Kim J, Xie L, Chen W, Li Z et al (2018) LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature 562:605\u2013609. https:\/\/doi.org\/10.1038\/s41586-018-0615-z","journal-title":"Nature"},{"key":"6121_CR28","doi-asserted-by":"publisher","unstructured":"Hu C, Cao Y, Li P, Tang X, Yang M, Gu S et al (2021) Oleanolic Acid Induces Autophagy and Apoptosis via the AMPK-mTOR Signaling Pathway in Colon Cancer. J Oncol 2021:8281718. https:\/\/doi.org\/10.1155\/2021\/8281718","DOI":"10.1155\/2021\/8281718"},{"key":"6121_CR29","doi-asserted-by":"publisher","unstructured":"Li S, Dong R, Kang Z, Li H, Wu X, Li T (2023) Exosomes: another intercellular lipometabolic communication mediators in digestive system neoplasms? Cytokine Growth Factor Rev 73. https:\/\/doi.org\/10.1016\/j.cytogfr.2023.06.005","DOI":"10.1016\/j.cytogfr.2023.06.005"},{"key":"6121_CR30","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3389\/fcell.2020.00812","volume":"8","author":"X Wu","year":"2020","unstructured":"Wu X, Yan F, Wang L, Sun G, Liu J, Qu M et al (2020) MicroRNA: another Pharmacological avenue for colorectal cancer? Front Cell Dev Biol 8:812. https:\/\/doi.org\/10.3389\/fcell.2020.00812","journal-title":"Front Cell Dev Biol"},{"key":"6121_CR31","doi-asserted-by":"publisher","unstructured":"Cao Z, Wang Z, Yang L, Li T, Tao X, Niu X (2025) Reshaping the immune microenvironment and reversing Immunosenescence by natural products: prospects for immunotherapy in gastric cancer. Semin Cancer Biol 110. https:\/\/doi.org\/10.1016\/j.semcancer.2025.02.002","DOI":"10.1016\/j.semcancer.2025.02.002"},{"key":"6121_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semcancer.2022.09.005","volume":"86","author":"T Li","year":"2022","unstructured":"Li T, Qiao T (2022) Unraveling tumor microenvironment of small-cell lung cancer: implications for immunotherapy. Semin Cancer Biol 86:117\u2013125. https:\/\/doi.org\/10.1016\/j.semcancer.2022.09.005","journal-title":"Semin Cancer Biol"},{"key":"6121_CR33","doi-asserted-by":"publisher","first-page":"880478","DOI":"10.3389\/fonc.2022.880478","volume":"12","author":"G Bao","year":"2022","unstructured":"Bao G, Li T, Guan X, Yao Y, Liang J, Xiang Y et al (2022) Development of a prognostic alternative splicing signature associated with tumor microenvironment immune profiles in lung adenocarcinoma. Front Oncol 12:880478. https:\/\/doi.org\/10.3389\/fonc.2022.880478","journal-title":"Front Oncol"},{"key":"6121_CR34","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1097\/CM9.0000000000003195","volume":"137","author":"M Li","year":"2024","unstructured":"Li M, Zhao X (2024) Leukocyte immunoglobulin-like receptor B4 (LILRB4) in acute myeloid leukemia: from prognostic biomarker to immunotherapeutic target. Chin Med J (Engl) 137:2697\u20132711. https:\/\/doi.org\/10.1097\/CM9.0000000000003195","journal-title":"Chin Med J (Engl)"},{"key":"6121_CR35","doi-asserted-by":"publisher","first-page":"143683","DOI":"10.1016\/j.ijbiomac.2025.143683","volume":"311","author":"Q Mai","year":"2025","unstructured":"Mai Q, Du Q, Zeng F, Chen Y, Wang X, Zou Q et al (2025) Galectin-3 suppresses CD8\u2009+\u2009T cells function via myeloid-derived suppressor cells recruitment in cervical cancer. Int J Biol Macromol 311:143683. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.143683","journal-title":"Int J Biol Macromol"},{"key":"6121_CR36","doi-asserted-by":"publisher","first-page":"9619","DOI":"10.1038\/s41598-022-13855-1","volume":"12","author":"Y Liang","year":"2022","unstructured":"Liang Y, Wang W, Zhu X, Yu M, Zhou C (2022) Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer. Sci Rep 12:9619. https:\/\/doi.org\/10.1038\/s41598-022-13855-1","journal-title":"Sci Rep"},{"key":"6121_CR37","doi-asserted-by":"publisher","first-page":"114605","DOI":"10.1016\/j.intimp.2025.114605","volume":"157","author":"Y Che","year":"2025","unstructured":"Che Y, Song B, Song Y, Sun J, Zhao X, Zheng J et al (2025) Thymoquinone enhances efficacy of cervical cancer therapeutic vaccines via modulating CD8\u2009+\u2009T cells. Int Immunopharmacol 157:114605. https:\/\/doi.org\/10.1016\/j.intimp.2025.114605","journal-title":"Int Immunopharmacol"},{"key":"6121_CR38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM (2018) CTLA-4: a moving target in immunotherapy. Blood 131:58\u201367. https:\/\/doi.org\/10.1182\/blood-2017-06-741033","journal-title":"Blood"},{"key":"6121_CR39","doi-asserted-by":"publisher","first-page":"101480","DOI":"10.1016\/j.smim.2021.101480","volume":"52","author":"KE Pauken","year":"2021","unstructured":"Pauken KE, Torchia JA, Chaudhri A, Sharpe AH, Freeman GJ (2021) Emerging concepts in PD-1 checkpoint biology. Semin Immunol 52:101480. https:\/\/doi.org\/10.1016\/j.smim.2021.101480","journal-title":"Semin Immunol"},{"key":"6121_CR40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","volume":"38","author":"A Rotte","year":"2019","unstructured":"Rotte A (2019) Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res 38:255. https:\/\/doi.org\/10.1186\/s13046-019-1259-z","journal-title":"J Exp Clin Cancer Res"},{"key":"6121_CR41","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1200\/JCO.21.02067","volume":"40","author":"DM O\u2019Malley","year":"2022","unstructured":"O\u2019Malley DM, Neffa M, Monk BJ, Melkadze T, Huang M, Kryzhanivska A et al (2022) Dual PD-1 and CTLA-4 checkpoint Blockade using balstilimab and Zalifrelimab combination as Second-Line treatment for advanced cervical cancer: an Open-Label phase II study. J Clin Oncol 40:762\u2013771. https:\/\/doi.org\/10.1200\/JCO.21.02067","journal-title":"J Clin Oncol"},{"key":"6121_CR42","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-023-01445-1","volume":"16","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Ma Y, Zang A, Cheng Y, Zhang Y, Wang X et al (2023) First-in-human phase I\/Ib study of QL1706 (PSB205), a bifunctional PD1\/CTLA4 dual blocker, in patients with advanced solid tumors. J Hematol Oncol 16:50. https:\/\/doi.org\/10.1186\/s13045-023-01445-1","journal-title":"J Hematol Oncol"},{"key":"6121_CR43","first-page":"1361","volume":"37","author":"I Rousalova","year":"2010","unstructured":"Rousalova I, Krepela E (2010) Granzyme B-induced apoptosis in cancer cells and its regulation (review). Int J Oncol 37:1361\u20131378","journal-title":"Int J Oncol"},{"key":"6121_CR44","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1158\/2326-6066.CIR-19-0036","volume":"7","author":"X Gui","year":"2019","unstructured":"Gui X, Deng M, Song H, Chen Y, Xie J, Li Z et al (2019) Disrupting LILRB4\/APOE interaction by an efficacious humanized antibody reverses T-cell suppression and blocks AML development. Cancer Immunol Res 7:1244\u20131257. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0036","journal-title":"Cancer Immunol Res"},{"key":"6121_CR45","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1080\/10428194.2020.1723014","volume":"61","author":"KS Chien","year":"2020","unstructured":"Chien KS, Class CA, Montalban-Bravo G, Wei Y, Sasaki K, Naqvi K et al (2020) LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. Leuk Lymphoma 61:1493\u20131499. https:\/\/doi.org\/10.1080\/10428194.2020.1723014","journal-title":"Leuk Lymphoma"},{"key":"6121_CR46","doi-asserted-by":"publisher","first-page":"1105265","DOI":"10.3389\/fimmu.2023.1105265","volume":"14","author":"L Yu","year":"2023","unstructured":"Yu L, Lanqing G, Huang Z, Xin X, Minglin L, Fa-Hui L et al (2023) T cell immunotherapy for cervical cancer: challenges and opportunities. Front Immunol 14:1105265. https:\/\/doi.org\/10.3389\/fimmu.2023.1105265","journal-title":"Front Immunol"},{"key":"6121_CR47","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev-immunol-082223-044122","volume":"43","author":"L Rausch","year":"2025","unstructured":"Rausch L, Kallies A (2025) Molecular mechanisms governing CD8 T cell differentiation and checkpoint inhibitor response in cancer. Annu Rev Immunol 43:515\u2013543. https:\/\/doi.org\/10.1146\/annurev-immunol-082223-044122","journal-title":"Annu Rev Immunol"},{"key":"6121_CR48","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12974-024-03206-4","volume":"21","author":"Y Ma","year":"2024","unstructured":"Ma Y, Zheng K, Zhao C, Chen J, Chen L, Zhang Y et al (2024) Microglia LILRB4 upregulation reduces brain damage after acute ischemic stroke by limiting CD8\u2009+\u2009T cell recruitment. J Neuroinflammation 21:214. https:\/\/doi.org\/10.1186\/s12974-024-03206-4","journal-title":"J Neuroinflammation"},{"key":"6121_CR49","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar V, Patel S, Tcyganov E, Gabrilovich DI (2016) The nature of Myeloid-Derived suppressor cells in the tumor microenvironment. Trends Immunol 37:208\u2013220. https:\/\/doi.org\/10.1016\/j.it.2016.01.004","journal-title":"Trends Immunol"},{"key":"6121_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13045-024-01529-6","volume":"17","author":"Z Zhao","year":"2024","unstructured":"Zhao Z, Qin J, Qian Y, Huang C, Liu X, Wang N et al (2024) FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion. J Hematol Oncol 17:9. https:\/\/doi.org\/10.1186\/s13045-024-01529-6","journal-title":"J Hematol Oncol"},{"key":"6121_CR51","doi-asserted-by":"publisher","first-page":"107521","DOI":"10.1016\/j.phrs.2024.107521","volume":"210","author":"T Xia","year":"2024","unstructured":"Xia T, Zhang Y, Peng H, Jia X, Yang D, Wei L et al (2024) EVA1B facilitates esophageal squamous carcinoma progression and recruitment of immunosuppressive myeloid-derived suppressor cells in the tumor microenvironment. Pharmacol Res 210:107521. https:\/\/doi.org\/10.1016\/j.phrs.2024.107521","journal-title":"Pharmacol Res"},{"key":"6121_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.05.032","author":"X Kang","year":"2025","unstructured":"Kang X, Li Y, Han Y, Wu M, Qian P, Dong J et al (2025) Dual Blockade of TNFR2 and CD47 reshape tumor immune microenvironment and improve antitumor effects in colorectal cancer. Mol Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2025.05.032","journal-title":"Mol Ther"},{"key":"6121_CR53","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12575-025-00279-0","volume":"27","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Teng W, Wu J, Luo Y, Wang Y, Li Y (2025) Piperlongumine inhibits lung cancer growth by inducing Endoplasmic reticulum stress leading to suppression of M2 macrophage polarization. Biol Proced Online 27:18. https:\/\/doi.org\/10.1186\/s12575-025-00279-0","journal-title":"Biol Proced Online"},{"key":"6121_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.05.004","author":"K Kersten","year":"2022","unstructured":"Kersten K, Hu KH, Combes AJ, Samad B, Harwin T, Ray A et al (2022) Spatiotemporal co-dependency between macrophages and exhausted CD8\u2009+\u2009T cells in cancer. Cancer Cell 40. https:\/\/doi.org\/10.1016\/j.ccell.2022.05.004","journal-title":"Cancer Cell 40"},{"key":"6121_CR55","doi-asserted-by":"publisher","first-page":"114906","DOI":"10.1016\/j.intimp.2025.114906","volume":"160","author":"L Hou","year":"2025","unstructured":"Hou L, Jiang M, Li Y, Cheng J, Liu F, Han X et al (2025) Targeting SPP1\u2009+\u2009macrophages via the SPP1-CD44 axis reveals a key mechanism of immune suppression and tumor progression in ovarian cancer. Int Immunopharmacol 160:114906. https:\/\/doi.org\/10.1016\/j.intimp.2025.114906","journal-title":"Int Immunopharmacol"},{"key":"6121_CR56","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1172\/JCI118271","volume":"96","author":"S Bellosta","year":"1995","unstructured":"Bellosta S, Mahley RW, Sanan DA, Murata J, Newland DL, Taylor JM et al (1995) Macrophage-specific expression of human Apolipoprotein E reduces atherosclerosis in hypercholesterolemic Apolipoprotein E-null mice. J Clin Invest 96:2170\u20132179","journal-title":"J Clin Invest"},{"key":"6121_CR57","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1161\/01.RES.0000187467.67684.43","volume":"97","author":"K Ali","year":"2005","unstructured":"Ali K, Middleton M, Pur\u00e9 E, Rader DJ (2005) Apolipoprotein E suppresses the type I inflammatory response in vivo. Circ Res 97:922\u2013927","journal-title":"Circ Res"},{"key":"6121_CR58","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1006\/cimm.1994.1302","volume":"159","author":"ME Kelly","year":"1994","unstructured":"Kelly ME, Clay MA, Mistry MJ, Hsieh-Li HM, Harmony JA (1994) Apolipoprotein E Inhibition of proliferation of mitogen-activated T lymphocytes: production of Interleukin 2 with reduced biological activity. Cell Immunol 159:124\u2013139","journal-title":"Cell Immunol"},{"key":"6121_CR59","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1158\/0008-5472.CAN-20-3929","volume":"81","author":"SB Kemp","year":"2021","unstructured":"Kemp SB, Carpenter ES, Steele NG, Donahue KL, Nwosu ZC, Pacheco A et al (2021) Apolipoprotein E promotes immune suppression in pancreatic cancer through NF-\u03baB-Mediated production of CXCL1. Cancer Res 81:4305\u20134318. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3929","journal-title":"Cancer Res"},{"key":"6121_CR60","doi-asserted-by":"publisher","first-page":"7032","DOI":"10.1002\/cam4.2587","volume":"8","author":"L Ren","year":"2019","unstructured":"Ren L, Yi J, Li W, Zheng X, Liu J, Wang J et al (2019) Apolipoproteins and cancer. Cancer Med 8:7032\u20137043. https:\/\/doi.org\/10.1002\/cam4.2587","journal-title":"Cancer Med"},{"key":"6121_CR61","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1158\/0008-5472.331.65.1","volume":"65","author":"Y-C Chen","year":"2005","unstructured":"Chen Y-C, Pohl G, Wang T-L, Morin PJ, Risberg B, Kristensen GB et al (2005) Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res 65:331\u2013337","journal-title":"Cancer Res"},{"key":"6121_CR62","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1158\/2326-6066.CIR-19-0315","volume":"8","author":"G Galliverti","year":"2020","unstructured":"Galliverti G, Wullschleger S, Tichet M, Murugan D, Zangger N, Horton W et al (2020) Myeloid cells orchestrate systemic Immunosuppression, impairing the efficacy of immunotherapy against HPV+ cancers. Cancer Immunol Res 8:131\u2013145. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0315","journal-title":"Cancer Immunol Res"},{"key":"6121_CR63","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0753-3322(00)88505-4","volume":"53","author":"H Le Buanec","year":"1999","unstructured":"Le Buanec H, Lachgar A, D\u2019Anna R, Zagury JF, Bizzini B, Bernard J et al (1999) Induction of cellular immunosuppression by the human papillomavirus type 16 E7 oncogenic protein. Biomed Pharmacother 53:323\u2013328","journal-title":"Biomed Pharmacother"},{"key":"6121_CR64","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K (2022) Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer 21:28. https:\/\/doi.org\/10.1186\/s12943-021-01489-2","journal-title":"Mol Cancer"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-026-06121-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-026-06121-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-026-06121-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:02:45Z","timestamp":1773248565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-026-06121-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6121"],"URL":"https:\/\/doi.org\/10.1007\/s00018-026-06121-4","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent to participate All human sample studies (including mRNA-seq) were approved by the Ethics Committee of the Cancer Hospital of Dalian University of Technology and complied with the Declaration of Helsinki. All animal experimentation protocols were approved by the Medical Ethics Committee of China Medical University and in accordance with the Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The informed consent of all the individual participants included in the study has been obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"146"}}